Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Seer, a diagnostics start-up based in South San Francisco, has launched with $36 million in series A and B financing to develop liquid biopsies for early detection of cancer and neurological diseases. Many companies developing liquid biopsies are focused on using trace pieces of DNA in the blood. Seer is developing proteomics-based biopsies to spot scarce proteins in the blood that could be a signal of disease. CEO Omid Farokhzad cofounded Seer based on his work at Harvard Medical School.
This article has been sent to the following recipient: